Photo of Gregory A. Morris, Ph.D.Photo of Gregory A. Morris, Ph.D.

Gregory A. Morris, Ph.D.

Partner
Leader, Life Sciences Litigation Practice Group

Education

Fordham University School of Law, J.D.
  • Fordham Intellectual Property Media & Entertainment Law Journal, Associate Editor
Northwestern University, Ph.D.
  • Organic Chemistry
University of Michigan, B.A.
  • English Literature

Prior Employment

  • Paul Hastings LLP, Of Counsel, 2012-2015
  • Kirkland & Ellis LLP, Partner, 2005-2012
  • Fish & Neave LLP, Associate/Patent Agent, 2001-2005

Bar Admissions

Court Admissions

Professional Affiliations

Intellectual Property Owners Association

New York Intellectual Property Law Association

Overview
Experience
News & Resources
Honors

Overview

Gregory Morris is the Leader of Honigman's Life Sciences Litigation Practice Group and is based in the Chicago office.  Dr. Morris focuses his practice on patent litigation, including trial proceedings before the United States Patent and Trademark Office (USPTO), and his experience includes representing clients in cases involving a wide range of technologies. His particular focus is on pharmaceutical, biotechnology, and medical device patent litigation. Dr. Morris also has experience in patent counseling and due diligence work.

Prior to law school, Dr. Morris earned a Ph.D. in Organic Chemistry from Northwestern University.  His scientific research led to eight peer-reviewed scientific publications.

Experience

Significant representative matters include:

  • Supernus Pharmaceuticals: Trial counsel for patentee, Supernus, in three IPRs filed by Amneal Pharmaceuticals who was seeking to sell generic Oracea®. Obtained first win after final written decision for a pharmaceutical company in an IPR proceeding, upholding the validity of three patents. (Petition for Inter Partes Review by Amneal Pharms. LLC, IPR2013-00368, IPR2013-00371, IPR2013-00372 (PTAB))
  • Galderma Labs. and Supernus Pharmaceuticals: Litigation counsel for Galderma and Supernus in ANDA case against Amneal Pharmaceuticals who was seeking to sell generic Oracea®. (Galderma Labs. et al. v. Amneal Pharms. et al., Civil Action No. 1-11-CV-01106 (D. Del.))
  • Sanofi-Aventis: Trial counsel for Sanofi in ANDA case against multiple applicants seeking to sell generic Uroxatral®. Obtained judgment for client after bench trial. (In re: Alfuzosin Hydrochloride Patent Litigation, Civil Action No. 08-md-1941 (D. Del.))
  • Forest Labs and Lundbeck: Trial counsel for Forest and Lundbeck in ANDA case against multiple applicants seeking to sell generic Lexapro®. Obtained judgment for client after bench trial. (Forest Labs., Inc., et al. v. Ivax Pharmaceuticals Inc. et al., Civil Action No. 03-891 (D. Del.))
  • Alexion Pharmaceuticals: Litigation counsel for Alexion in patent infringement case brought by PDL involving client's humanized antibody drug Soliris®. (PDL Biopharma, Inc. v. Alexion Pharmaceuticals, Inc., Civil Action No. 07-156 (D. Del.))

News & Resources

Publications

Seminars & Events

Honors

  • Managing Intellectual Property
    • Recognized as an "IP Patent Star," 2016
    • Recognized as an "IP Star," 2016
  • Illinois Super Lawyers
    • Recognized as a Rising Star, 2015
  • New York Super Lawyers
    • Recognized as a Rising Star, 2013-2015